GSD Share Price Performance
Recent GSD News & Updates
No updates
Devonian Health Group Inc. Key Details
Last Reported Earnings
Apr 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.029
- Gross Margin
- 33.10%
- Net Profit Margin
- -13.84%
- Debt/Equity Ratio
- 0%
Devonian Health Group Inc. Competitors
About GSD
- Founded
- n/a
- Employees
- 7
- CEO
- WebsiteView website
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; Dexlansoprazole; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the Purgenesis name. Devonian Health Group Inc. is headquartered in Québec, Canada.
Canadian Market Performance
- 7 Days: 0.9%
- 3 Months: 11.7%
- 1 Year: 17.4%
- Year to Date: 10.1%
The Consumer Staples sector gained 3.6% while the market remained flat over the last week. Meanwhile, the market is actually up 17% over the past year. Looking forward, earnings are forecast to grow by 12% annually. Market details ›
The tide is turning for UK & European markets. Index ETFs won’t cut it since sector spreads are massive. Picking the right companies matters now more than ever.
Continue readingLast Week
